Before antibiotics were discovered in the 20th century, contracting an infection could be a death sentence. Their discovery was a turning point in human history, revolutionizing medicine and saving countless lives. However, the growing burden of antimicrobial resistance (AMR) threatens the return to a world without antibiotics.
We all have a responsibility to address this threat, and it will take dedicated efforts from all sectors across health care – including patients – to make a difference.
One. Patients (all of us!): Be vigilant in prevention efforts and always use antibiotics correctly
We each play an important role in slowing the threat of AMR— starting with preventing infections that require antibiotics in the first place. Washing hands, preparing food hygienically and keeping up-to-date with vaccinations are all effective measures we can take to help avoid infections.
Another important action patients can take is using antibiotics only when they are needed. Always follow prescription directions and never share or take leftover antibiotics, which could contribute to the build-up of resistance. If your doctor believes antibiotics are not the correct treatment to help your condition, ask about other options. Taking antibiotics when they’re not needed may advance the spread of AMR. Bottom line: listen to your doctor.
Two. Health care professionals: Be a source of antibiotic guidance
Doctors and medical systems need to preserve the effectiveness of antibiotics. It’s up to the health care providers to ensure that the right treatment is given based on an accurate diagnosis. Hospitals should have a plan in place, with principles customized to their local needs, to guide the appropriate use of these medicines.
Three. Policymakers: Encourage antimicrobial innovation
To help slow the advance of AMR, we need new antibiotic options to stay one step ahead of the evolving bacteria. Governments can help. Incentives packages can provide a sustainable return on investment for new antimicrobials. Encouraging innovation would allow companies to invest in the research and development needed. As a result, this would help provide health care professionals around the world with the tools they need to help patients fighting infections.
Four. Industry leaders: Invest in new developments
Finally, the participation of leading biopharmaceutical companies is crucial to addressing the growing threat of AMR. Despite market challenges, Merck is one of the only large biopharmaceutical companies that remains committed to inventing new solutions through early- and late-stage research and development in infectious disease.
And, in an effort to affect widespread change, we’ve supported efforts around the world that aim to address this global threat through surveillance initiatives, collaborating with hospitals to fund education and implement effective programs, and advocating for substantial policy changes.
Merck is proud to be a leader in the effort to slow AMR. But we know we cannot solve the problem on our own. It’s up to all of us to take collective action, and we hope you’ll join our efforts and play your individual part.
Published November 2019
Copyright. © 2009-2019 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved.
This website of Merck & Co., Inc., Kenilworth, NJ, USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation in the United States and internationally; global trends toward healthcare cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2015 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.
Merck is known as MSD outside the United States and Canada. Clicking on any of the links below will take you to a website intended for those living outside the United States and Canada.